Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.86 |
| ▸ | BCL2 | P10415 | 15/20 | 0.86 |
| ▸ | BAD | Q92934 | 4/20 | 0.86 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.86 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.86 |
| ▸ | ASPH | Q12797 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025585 | 0.96 | BCL2L1 (0.90) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1955579 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL1954932 | 0.96 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL685145 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19145101 | 0.93 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19145093 | 0.93 | BCL2L1 (0.93) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL25639818 | 0.93 | BCL2L1 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2024972 | 0.93 | BCL2L1 (0.96) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL2022422 | 0.93 | BCL2L1 (0.96) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| Navitoclax SCHEMBL10316178 | 0.93 | BCL2L1 (1.00) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390799-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-06-24 | — | — | US | claimed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBVIE INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | ABBVIE INC. | 2016-04-14 | — | — | US | disclosed |
| EP-1888550-B1 | Apoptosis promoters | ABBVIE BAHAMAS LTD (BS) | 2014-06-25 | — | — | EP | disclosed |
| US-8624027-B2 | Combination therapy for treating cancer and diagnostic assays for use therein | ABBVIE INC. (US) | 2014-01-07 | — | — | US | disclosed |
| WO-2009064938-A1 | METHOD OF TREATING ARTHRITIS | ABBOTT LABORATORIES (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080287419-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-07-31 | — | — | US | disclosed |
| US-7390799-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2008064116-A2 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1888550-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007040650-A9 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007040650-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | ABBVIE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2L1 953/4885BCL2 520/4885BAD 421/4885 |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | MMP1, COL2A1, MMP13 | BCL2L1 1304/4885BCL2 147/4885BAD 1571/4885 |
| US-20080287419-A1 | APOPTOSIS PROMOTERS | BAX, API5, BCL2 | BCL2L1 12/4885BCL2 3/4885BAD 6/4885 |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | BAX, BCL2L1, BCL2A1 | BCL2L1 2/4885BCL2 4/4885BAD 9/4885 |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | BCL2, BAX, BCLAF1 | BCL2L1 7/4885BCL2 1/4885BAD 10/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885BAD 16/4885 |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885BAD 445/4885 |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885BAD 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.